Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Exco InTouch Joins C-Path ePRO Consortium

Published: Tuesday, May 21, 2013
Last Updated: Tuesday, May 21, 2013
Bookmark and Share
Company joins ePRO Consortium to advance electronic data capture in clinical trials.

Exco InTouch has announced that it has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a programme run by the Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals.

The ePRO Consortium is committed to improving the quality, practicality and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment.

As PRO endpoints have become increasingly common in studies for evaluating patients’ perspectives of a particular drug, the requirement for better measures of patients’ experiences has become even more critical.

Exco InTouch will work closely with other Consortium members from a number of industry-leading providers of innovative electronic data collection technologies, to develop guidelines for the adaptation of PRO measures to the appropriate ePRO solutions.

The ePRO Consortium will generate measurement equivalence data, develop specification documents and data standards, and produce methodological guidance on measurement issues related to ePRO applications.

The association will also work closely with C-Path’s PRO Consortium, a group of 25 pharmaceutical companies working to develop novel PRO measures, with the goal of making these new measures available for electronic data capture formats.

The aim of the programme is to enhance public health by optimizing the value of PRO data in medical product evaluation and clinical decision making.

“Exco InTouch is delighted to join the ePRO Consortium to help advance the science of electronic data capture and create standardized guidelines to ensure all data collated electronically in clinical trials is valid and reliable,” comments Tim Davis, CEO of Exco InTouch.

Davis continued, “The Consortium provides a neutral and collaborative environment for the industry to work together to develop and advocate consistent approaches for drug development.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exco InTouch, Pharma’s Only Representative on Sunday Times Hiscox Tech Track 100
The pharma tech innovator has tripled turnover in the last three years.
Saturday, September 12, 2015
Exco InTouch Predicts Strong Growth in Mobile ePRO
The cost and time efficient approach enables safe, secure collection of patient data, bolsters engagement and is applicable for both BYOD and provisioned devices.
Friday, August 21, 2015
Exco InTouch Granted United States Patent for mDNA® Technology
An automated management tool that identifies, distributes and manages patients and their mobile device.
Thursday, July 23, 2015
Exco InTouch Unveils Comprehensive White Paper on Effective Mobile Strategies
The company, together with leading academic experts, has produced a highly definitive guide for the industry.
Thursday, June 04, 2015
Exco InTouch Shortlisted for the Best Technological Development in Clinical Trials 2014 SCRIP Award
Selection for the accolade shortlist recognizes the company’s mDNA® technology project team - leading the way with innovation in the field of patient engagement and data capture solutions to enhance efficiencies in clinical trials.
Wednesday, October 08, 2014
Exco InTouch Shortlisted for the Best Technological Development in Clinical Trials 2014 SCRIP Award
Selection for the accolade shortlist recognizes the company’s mDNA® technology project team - leading the way with innovation in the field of patient engagement and data capture solutions to enhance efficiencies in clinical trials.
Saturday, October 04, 2014
Pharma Industry Encouraged to Adopt Mobile ePRO for Clinical Trials Efficiency at DIA 2014
Exco InTouch outlines strategies to introduce mobile solutions into clinical trials at DIA Annual Meeting.
Friday, June 06, 2014
Exco InTouch Unveils Exco™ Valued Partner Network
Innovative partner network to facilitate integration of digital patient engagement and data capture in clinical research programs.
Friday, March 28, 2014
Laurence Burke Joins Exco InTouch as Vice President of Operations
Position set to ensure provision of robust, streamlined and efficient patient engagement and data capture programs applied across clinical, late phase and mHealth sectors.
Thursday, February 20, 2014
Exco InTouch Successfully Completes HIPAA Security Audit
Audit to assess compliance utilizing the NIST guidelines for HIPAA security.
Wednesday, January 22, 2014
Exco InTouch Continues Significant Growth with Appointment of CTO
Appointment of Madhav Vattikuti as chief technology officer.
Thursday, February 02, 2012
Exco InTouch Wins EOA for Second Year Running
Company wins ‘Best eBusiness/IT Strategy’ award at European Outsourcing Awards 2011.
Friday, November 04, 2011
Exco Intouch Secures Growth Investment from SEP
Mobile patient communication leader to use funds to accelerate growth strategy.
Tuesday, October 04, 2011
Exco InTouch Receives ePRO Accolade at the 2010 European Outsourcing Awards
Exco InTouch has been recognised for its delivery of electronic Patient Reported Outcomes (ePRO) solutions at the 2010 European Outsourcing Awards. The award for Most Innovative Relationship was in recognition of their collaborative study with The University of Queensland.
Thursday, November 25, 2010
mobilePRO Solution for Patient Data Capture by Exco InTouch
New mobilePRO technology is a powerful solution that overcomes issues associated with traditional ePRO.
Monday, August 23, 2010
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos